Cheson heads Lymphoma Research Foundation board

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 7
Volume 19
Issue 7

Bruce Cheson, MD, has become chair of the Lymphoma Research Foundation Scientific Advisory Board. Dr. Cheson is professor of medicine, head of hematology, and director of hematology research at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington DC. His two-year term as chair began in July 2010.

Bruce Cheson, MD, has become chair of the Lymphoma Research Foundation Scientific Advisory Board. Dr. Cheson is professor of medicine, head of hematology, and director of hematology research at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington DC. His two-year term as chair began in July 2010.

Dr. Cheson's clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies. He currently serves as editor-in-chief of Clinical Lymphoma, Myeloma & Leukemia and Clinical Advances in Hematology and Oncology.

The 40-member scientific board develops the foundation's research portfolio, reviews grant proposals, and makes recommendations about research priorities and funding to the New York-based foundation's board of directors.

Dr. Cheson serves on the Oncology News International editorial advisory board.

Recent Videos
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content